NL-OMON36684撤回3 期
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn*s Disease (CCX114644) - CCX114644
适应症
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Completion of the placebo-controlled induction study, CCX114151, without achieving clinical response or remission or completion of maintenance study CCX114157, withdrawal from maintenance study CCX114157 due to worsening of Crohn*s disease.
- •* Safe contraception for women of childbearing potential.
排除标准
- •* Breastfeeding, pregnancy.
- •* Known coeliac disease, those who follow a gluten-free diet to manage symptoms of suspected coeliac disease and subjects with a positive screening test for celiac disease.
- •* Known or suspected small bowel stricture
- •* Enterocutaneous, abdominal or pelvic fistulae with abscesses or fistulae likely to require surgery during the study period.
研究者
相似试验
进行中（未招募）
不适用
An Open-Label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects with Renal Cell Carcinoma previously enrolled on Protocol VEG105192Renal Cell CarcinomaMedDRA version: 8.1Level: LLTClassification code 10038415Term: Renal cell carcinoma stage unspecifiedEUCTR2006-002381-18-GRGlaxoSmithKline Research & Development Limited132
进行中（未招募）
1 期
An Open-Label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects with Renal Cell Carcinoma previously enrolled on Protocol VEG105192Renal Cell CarcinomaEUCTR2006-002381-18-GBGlaxoSmithKline Research & Development Limited
进行中（未招募）
不适用
An Open-Label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects with Renal Cell Carcinoma previously enrolled on Protocol VEG105192Renal Cell CarcinomaEUCTR2006-002381-18-IEGlaxoSmithKline Research & Development Limited132
进行中（未招募）
不适用
A 25 month study of a potential new medicine (GSK1605786A) for the treatment of Crohn’s diseaseSubjects with Crohn’s DiseaseMedDRA version: 14.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-022384-35-GRGlaxoSmithKline Research & Development Ltd800
招募中
1 期
Open-Label Extension of Treprostinil Palmitil Inhalation Powder for Pulmonary Arterial HypertensioEUCTR2022-001951-18-ATInsmed Incorporated99